Modes of action of the new arylguanidine abafungin beyond interference with ergosterol biosynthesis and in vitro activity against medically important fungi

Chemotherapy

Volumn 54, Issue 4, 2008, Pages 245-259

  Borelli, C ^a   Schaller, M ^b   Niewerth, M ^a   Nocker, K ^c   Baasner, B ^d   Berg, D ^e   Tiemann, R ^e   Tietjen, K ^e   Fugmann, B ^d   Lang Fugmann, S ^d   Korting, H C ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c York Pharma AG   (Germany)

^d BaFuS GmbH   (Germany)

^e BAYER CROPSCIENCE AG   (Germany)

Author keywords

Abafungin; Antifungal agents; Arylguanidines; Azoles; Cell membrane; Ergosterol biosynthesis

Indexed keywords

ABAFUNGIN; ALLYLAMINE DERIVATIVE; AMOROLFINE; AMPHOTERICIN B; ANTIFUNGAL AGENT; BENZOFURAN DERIVATIVE; BIFONAZOLE; CASPOFUNGIN; CLOTRIMAZOLE; ERGOSTEROL; FAMOTIDINE; FLUCONAZOLE; FLUCYTOSINE; FLUOROURACIL; GRISEOFULVIN; IMIDAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MORPHOLINE DERIVATIVE; NYSTATIN; PIROCTONE ETHANOLAMINE; POLYENE; PYRIMIDINE DERIVATIVE; SINEFUNGIN; TERBINAFINE; THIOCARBAMIC ACID DERIVATIVE; TOLNAFTATE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ARTICLE; BIOSYNTHESIS; DRUG MECHANISM; DRUG STRUCTURE; DRUG SYNTHESIS; FUNGAL STRAIN; FUNGICIDAL ACTIVITY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; YEAST;

ADENOSINE TRIPHOSPHATE; ANTIFUNGAL AGENTS; CANDIDA ALBICANS; ERGOSTEROL; HYDROGEN-ION CONCENTRATION; MOLECULAR STRUCTURE; PYRIMIDINES; THIAZOLES;

EID: 50449104506     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000142334     Document Type: Article

References (41)

1. Vanden Bossche H, Dromer F, Improvisi I, Lozano-Chiu M, Rex JH, Sanglard D: Antifungal drug resistance in pathogenic fungi. Med Mycol 1998;36(suppl 1):119-128.
2. Shao PL, Huang LM, Hsueh PR: Recent advances and challenges in the treatment of invasive fungal infections. Int J Antimicrob Agents 2007;30:487-495.
3. Anderson JB: Evolution of antifungal-drug resistance: mechanisms and pathogen fitness. Nat Rev Microbiol 2005;3:547-556.
4. de Pauw BE, Meunier F: The challenge of invasive fungal infection. Chemotherapy 1999;45(suppl 1):1-14.
5. Zhang AY, Camp WL, Elewski BE: Advances in topical and systemic antifungals. Dermatol Clin 2007;25:165-183, vi.
6. Gupta AK, Tomas E: New antifungal agents. Dermatol Clin 2003;21:565-576.
7. Ghannoum MA, Rice LB: Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 1999;12:501-517.
8. Bastert J, Schaller M, Korting HC, Evans EG: Current and future approaches to antimycotic treatment in the era of resistant fungi and immunocompromised hosts. Int J Antimicrob Agents 2001;17:81-91.
9. Francois IE, Aerts AM, Cammue BP, Thevissen K: Currently used antimycotics: spectrum, mode of action and resistance occurrence. Curr Drug Targets 2005;6:895-907.
10. Polak A: Mode of action of morpholine derivatives. Ann NY Acad Sci 1988;544:221-228.
11. Bohme A, Karthaus M: Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium. Chemotherapy 1999;45:315-324.
12. Lupetti A, Danesi R, Campa M, Del Tacca M, Kelly S: Molecular basis of resistance to azole antifungals. Trends Mol Med 2002;8:76-81.
13. Gupta AK, Shear NH: Terbinafine: an update. J Am Acad Dermatol 1997;37:979-988.
14. Korting HC, Schäfer-Korting M: Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol 1992;128:243-248.
15. Edlind TD, Katiyar SK: The echinocandin 'target' identified by cross-linking is a homolog of Pil1 and Lsp1, sphingolipid-dependent regulators of cell wall integrity signaling. Antimicrob Agents Chemother 2004;48:4491.
16. Aperis G, Mylonakis E: Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006;15:579-602.
17. Shigematsu ML, Uno J, Arai T: Effect of ketoconazole on isolated mitochondria from Candida albicans. Antimicrob Agents Chemother 1982;21:919-924.
18. Sheehan DJ, Hitchcock CA, Sibley CM: Current and emerging azole antifungal agents. Clin Microbiol Rev 1999;12:40-79.
19. Leem SH, Park JE, Kim IS, Chae JY, Sugino A, Sunwoo Y: The possible mechanism of action of ciclopirox olamine in the yeast Saccharomyces cerevisiae. Mol Cells 2003;15:55-61.
20. Niewerth M, Kunze D, Seibold M, Schaller M, Korting HC, Hube B: Ciclopirox olamine treatment affects the expression pattern of Candida albicans genes encoding virulence factors, iron metabolism proteins, and drug resistance factors. Antimicrob Agents Chemother 2003;47:1805-1817.
21. Sigle HC, Thewes S, Niewerth M, Korting HC, Schäfer-Korting M, Hube B: Oxygen accessibility and iron levels are critical factors for the antifungal action of ciclopirox against Candida albicans. J Antimicrob Chemother 2005;55:663-673.
22. Polak A: Preclinical data and mode of action of amorolfine. Dermatology 1992;184(suppl 1):3-7.
23. Haria M, Bryson HM: Amorolfine. A review of its pharmacological properties and therapeutic potential in the treatment of onychomycosis and other superficial fungal infections. Drugs 1995;49:103-120.
24. Urbina JA, Cohen BE, Perozo E, Cornivelli L: Spin-labeled amphotericin B: synthesis, characterization, biological and spectroscopic properties. Biochim Biophys Acta 1987;897:467-473.
25. Polak A, Scholer HJ: Fungistatic activity, uptake and incorporation of 5-fluorocytosine in Candida albicans, as influenced by pyrimidines and purines. II. Studies on distribution and incorporation. Pathol Microbiol (Basel) 1973;39:334-337.
26. Ryder NS, Frank I, Dupont MC: Ergosterol biosynthesis inhibition by the thiocarbamate antifungal agents tolnaftate and tolciclate. Antimicrob Agents Chemother 1986;29:858-860.
27. Kanafani ZA, Perfect JR: Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin Infect Dis 2008;46:120-128.
28. White TC, Marr KA, Bowden RA: Clinical, cellular, and molecular factors that contribute to antifungal drug resistance. Clin Microbiol Rev 1998;11:382-402.
29. Barker KS, Rogers PD: Recent insights into the mechanisms of antifungal resistance. Curr Infect Dis Rep 2006;8:449-456.
30. Lundin A, Richardsson A, Thore A: Continuous monitoring of ATP-converting reactions by purified firefly luciferase. Anal Biochem 1976;75:611-620.
31. Epand RM, Jones AJ, Sayer B: Molecular interactions in the model lipoprotein complex formed between glucagon and dimyristoylglycerophosphocholine. Biochemistry 1977;16:4360-4368.
32. Schaller K, Itayama H, Tiemann R, Uchida K, Yamaguchi H: XII. Congress of the International Society for Human and Animal Mycology (ISHAM). Adelaide, South Australia, 1994, P7.3.
33. Berg D, Ytayama H, Schaller K, Tiemann R, Uchida K, Yamaguchi H, Zywitz A: XII. Congress of the International Society for Human and Animal Mycology (ISHAM). Adelaide, South Australia, 1994, PO2.52, D97.
34. Ryder NS: Effect of allylamine antimycotic agents on fungal sterol biosynthesis measured by sterol side-chain methylation. J Gen Microbiol 1985;131:1595-1602.
35. Agut J, Palacin C, Salgado J, Casas E, Sacristan A, Ortiz JA: Direct membrane-damaging effect of sertaconazole on Candida albicans as a mechanism of its fungicidal activity. Arzneimittelforschung 1992;42:721-724.
36. Bell JE, Hall C: UV and visible absorbance spectroscopy; in Ellis JE (ed): Spectroscopy in Biochemistry. (Boca Raton, CRC Press, 1981.
37. Mishra P, Bolard J, Prasad R: Emerging role of lipids of Candida albicans, a pathogenic dimorphic yeast. Biochim Biophys Acta 1992;1127:1-14.
38. 2+ ionophore in sterol-containing liposomes. Biochim Biophys Acta 1989;982:303-306.
39. Iwatani W, Arika T, Yamaguchi H: Two mechanisms of butenafine action in Candida albicans. Antimicrob Agents Chemother 1993;37:785-788.
40. Sud IJ, Feingold DS: Heterogeneity of action of mechanisms among antimycotic imidazoles. Antimicrob Agents Chemother 1981;20:71-74.
41. Ansehn S, Nilsson L: Direct membrane-damaging effect of ketoconazole and tioconazole on Candida albicans demonstrated by bioluminescent assay of ATP. Antimicrob Agents Chemother 1984;26:22-25.